Coronary Bypass Articles & Analysis
14 news found
Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21. The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...
The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. Myocardial infarction occurs after the patient has undergone stenting. ...
Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG – which is a coronary artery bypass graft; and its pulmonary heart valve, which was the first ever synthetic valve to enter a pivotal trial (Xplore2/Pivotal) in July this year. ...
The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, synthetic blood vessel device that turns into a living blood vessel when colonised by patient’s own ...
Leveraging the versatility of its technology platform, which can be used to improve many types of implants, Xeltis initiated the development of three types of cardiovascular implants: pulmonary heart valves, coronary artery bypass graft and haemodialysis access grafts, the roll-out of which is set to be accelerated by this EIB ...
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the ...
In addition to its restorative pulmonary valve, Xeltis has developed the first-ever restorative synthetic coronary artery bypass graft (CABG) to have shown successful long-term results in long preclinical trials and the first-ever restorative synthetic vascular access graft for patients that need ...
Mehran Khorsandi and medical devices engineer Henry Bourang, ABS is positioned to solve one of the most technically challenging problems – the treatment of coronary bifurcation lesions - that has eluded the medical device world since coronary stents were first implanted in humans in 1986. Coronary bifurcation lesions are prevalent in about ...
The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply. ...
The disease that Bilix has targeted is ischemic reperfusion injury caused by organ transplantation, myocardial infarction, coronary artery bypass grafting, and stroke. In the case of myocardial infarction, it occurs after a patient undergoes a stent procedure. ...
Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial with Elafin in ECS is in preparation. ...
Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial with Elafin in ECS is in preparation. ...
About Heartcel Heartcell is an allogeneic cell therapy containing off-the-shelf immunomodulatory progenitor (iMP) cells engineered to regenerate the heart. iMPs are administered during coronary artery bypass graft (CABG) surgery by direct injection around the cardiac scar that is to be regenerated. iMP cells have been designated an Advanced Therapeutic Medicinal ...
Heartcel, Celixir’s lead investigational cardiac regenerative medicine, is a tissue engineered medicine comprising allogeneic (off-the-shelf) immunomodulatory progenitor (iMP) cells and is designated as an advanced therapeutic medicinal product (ATMP) by the European Medicines Agency. iMP cells are a novel cell type engineered to reduce heart scarring and regenerate the heart in patients ...